NCT01144832

Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists

IBS Treatment With H1-receptor Antagonists

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: KU Leuven · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Purpose: To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine. Design: Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization). End points: End point is the effect of treatment on clinical symptoms and visceral hypersensitivity which will be evaluated with a barostat test.

Conditions

• Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	ebastine	20 milligram capsule once daily
DRUG	placebo capsule	one capsule once daily

Timeline

• Start date: 2009-10-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2010-06-16
• Last updated: 2016-01-28

Locations

1 site across 1 country: Belgium